Ellen Rosenberg - Amicus Therapeutics General Counsel and Corporate Secretary

FOLD Stock  USD 11.86  0.43  3.76%   

Executive

Ms. Ellen S. Rosenberg serves as Chief Legal Officer and Corporationrationrate Secretary of the Company. She has served as our Chief Legal Officer and Corporationrationrate Secretary since December 2018 and our General Counsel and Corporationrationrate Secretary since February 2016. Prior to joining Amicus, she served as a Senior Vice President of Shire Pharmaceuticals. Prior to Shire, Ms. Rosenberg was Associate General Counsel for the Metabolic Endocrinology division at EMD Serono Inc., the U.S. affiliate of Merck KGaA. Ms. Rosenberg brings extensive and broad ranging legal experience in the biopharmaceutical and medical device industry including mergers and acquisitions, licensing, corporate governance, product launches, risk management, litigation, investigations and compliance matters. Ms. Rosenberg also has significant experience building and developing legal teams and the inhouse legal function since 2018.
Age 61
Tenure 6 years
Address 47 Hulfish Street, Princeton, NJ, United States, 08542
Phone609 662 2000
Webhttps://amicusrx.com

Latest Insider Transactions

2024-02-06Disposed of 400 shares @ 13View
2023-12-27Disposed of 5000 shares @ 14.07View
Rosenberg received a B.A. from the University of Connecticut and a J.D. from the University of Pennsylvania Law School.

Amicus Therapeutics Management Efficiency

The company has return on total asset (ROA) of (0.0612) % which means that it has lost $0.0612 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0704) %, meaning that it created substantial loss on money invested by shareholders. Amicus Therapeutics' management efficiency ratios could be used to measure how well Amicus Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of March 28, 2024, Return On Capital Employed is expected to decline to -0.13. In addition to that, Return On Assets is expected to decline to -0.2. At present, Amicus Therapeutics' Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Fixed Asset Turnover is expected to grow to 7.23, whereas Other Assets are forecasted to decline to about 41.8 M.
The company currently holds 445.06 M in liabilities with Debt to Equity (D/E) ratio of 2.6, implying the company greatly relies on financing operations through barrowing. Amicus Therapeutics has a current ratio of 2.96, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Amicus Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Amicus Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Amicus Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Amicus to invest in growth at high rates of return. When we think about Amicus Therapeutics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Sara EvansAir Lease
N/A
Sabrina CPAAir Lease
N/A
Ryan McKennaAir Lease
N/A
David BekerAir Lease
N/A
Marius FurulySFL Corporation
N/A
Jason ArnoldAir Lease
N/A
Andr ReppenSFL Corporation
42
Rafael MiajaGrupo Aeroportuario Del
N/A
Dave SingletonFair Isaac
N/A
Nikhil BehlFair Isaac
50
Eric HoogenkampAir Lease
N/A
Joe RacanelliForsys Metals Corp
N/A
Don PetersonFair Isaac
62
James AyersSFL Corporation
42
Kevin KeifferEncore Wire
N/A
Manuel SolaGrupo Aeroportuario Del
61
Ana ChanonaGrupo Aeroportuario Del
N/A
Claudio MoralesGrupo Aeroportuario Del
73
William BigbeeEncore Wire
N/A
Emily HalversonAlaska Air Group
N/A
Daniel VerwholtAir Lease
N/A
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania. Amicus Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 496 people. Amicus Therapeutics (FOLD) is traded on NASDAQ Exchange in USA. It is located in 47 Hulfish Street, Princeton, NJ, United States, 08542 and employs 517 people. Amicus Therapeutics is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Amicus Therapeutics Leadership Team

Elected by the shareholders, the Amicus Therapeutics' board of directors comprises two types of representatives: Amicus Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Amicus. The board's role is to monitor Amicus Therapeutics' management team and ensure that shareholders' interests are well served. Amicus Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Amicus Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Hung Do, Senior Vice President - Discovery Biology
Robert Essner, Independent Director
John Kirk, Vice President - Regulatory Affairs
David Clark, Chief Officer
Andrew Mulberg, Vice President - Regulatory Strategy
Craig Wheeler, Independent Director
Daphne Quimi, Principal Accounting Officer, VP of Fin. and Corporate Controller
Bradley Campbell, Pres and COO
Burke Whitman, Independent Director
Enrique Dilone, Vice President - Technical Operations
John Crowley, Executive Chairman
Dipal Doshi, Senior Vice President - Business Planning and Development
Mark Baldry, Vice President of Global Marketing
Margaret McGlynn, Independent Director
Samantha Prout, Principal Accounting Officer, Controller
Bradley MBA, President CEO
Andrew Faughnan, Director Relations
Diana Moore, Head Communications
Kenneth Peist, Vice President - Legal and Intellectual Property
Ken Valenzano, Senior Vice President - Preclinical Research
Ted Love, Independent Director
Jay Barth, Chief Medical Officer
Jayne Gershkowitz, Vice President - Patient Advocacy & Public Policy
Donald Hayden, Lead Independent Director
Patrik Esq, Global Officer
Michael Raab, Independent Director
Sara Pellegrino, IR Contact Officer
Willem Weperen, Regional Vice President and Country Manager, International
Sol Barer, Independent Director
Julie Yu, Vice President - Clinical Operations and Data Management
Patrik Florencio, Global VP
William Baird, CFO
David Allsop, Senior Vice President - International
Lynn Bleil, Independent Director
Simon Harford, Chief Officer
Ellen Rosenberg, General Counsel and Corporate Secretary
Simon Jordan, Senior Vice President - International
Jill Weimer, Senior Vice President of Discovery Research and Gene Therapy Science
Glenn Sblendorio, Independent Director
Jeffrey Castelli, Vice President - Program and Portfolio Management
Kurt Andrews, Senior Vice President - Human Resources

Amicus Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Amicus Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Amicus Therapeutics is a strong investment it is important to analyze Amicus Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amicus Therapeutics' future performance. For an informed investment choice regarding Amicus Stock, refer to the following important reports:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Amicus Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.
You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.

Complementary Tools for Amicus Stock analysis

When running Amicus Therapeutics' price analysis, check to measure Amicus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amicus Therapeutics is operating at the current time. Most of Amicus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Amicus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amicus Therapeutics' price. Additionally, you may evaluate how the addition of Amicus Therapeutics to your portfolios can decrease your overall portfolio volatility.
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Is Amicus Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amicus Therapeutics. If investors know Amicus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amicus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.51)
Revenue Per Share
1.353
Quarterly Revenue Growth
0.306
Return On Assets
(0.06)
Return On Equity
(1.07)
The market value of Amicus Therapeutics is measured differently than its book value, which is the value of Amicus that is recorded on the company's balance sheet. Investors also form their own opinion of Amicus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Amicus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amicus Therapeutics' market value can be influenced by many factors that don't directly affect Amicus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amicus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amicus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amicus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.